Publications by authors named "Ana Lopez Lirola"
Article Synopsis
- The study assessed the safety and effectiveness of a two-pill HIV treatment regimen (BIC/FTC/TAF plus darunavir/cobicistat) for individuals with a history of treatment difficulties.
- The trial had 63 participants, mainly men, who were stable on a more complex regimen and showed high rates of maintaining low viral loads after 48 weeks.
- Results indicated the new regimen is well-tolerated, potentially enhancing adherence and long-term success in managing HIV for heavily treatment-experienced individuals.
Objective: To analyse the effectiveness and safety of daptomycin versus vancomycin on the management catheter-related bloodstream nfections in oncology patients.
Method: A retrospective study was carried out including all patients admitted at the Medical Oncology Unit between 2010 and 2018 with positive blood cultures confirmed catheter-related bloodstream infections due to gram- positive microorganism, who were treated with either vancomycin or daptomycin. The primary end point was all cause 30-days mortality, 30-days hospital readmission and length of hospital stay (length of hospital stay).
Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our objectives were to determine the real-life effectiveness and safety of DT with dolutegravir (50 mg/QD) plus lamivudine (300 mg/QD) in a multiple-tablet regimen (MTR) in naïve PLHIV followed up for 48 weeks and to evaluate the compliance and satisfaction of patients. Material and methods: An open, single-arm, multicenter, non-randomized clinical trial from May 2019 through September 2020 with a 48-week follow-up.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to identify mutations in the HIV-1 reverse transcriptase (RT) related to therapy failure from different nucleoside analogues.
- The analysis involved RT sequences from 1893 HIV-1 isolates, revealing significant mutations linked to therapy failure, particularly in the thumb subdomain of RT.
- Results indicated that specific mutations, such as A272P, K277R, and V293I, were more common in patients who experienced treatment failure, highlighting their potential role in the effectiveness of nucleoside analogue therapies.